Unless otherwise defined herein, the capitalised terms used in
this announcement have the same meaning as those used in the
Company's announcements released on 3 July 2024.
5 July 2024
Physiomics
Plc
("Physiomics" or the
"Company")
Result of WRAP Retail
Offer
Physiomics plc, (AIM: PYC), is
pleased to announce, further to the announcements on 3 July 2024,
the completion of the WRAP Retail Offer, at the same issue price as
the previously announced Placing (together, the "Fundraise"). The WRAP Retail Offer,
which closed at 4:30 p.m. yesterday and which was oversubscribed,
has raised gross proceeds of £25,000 through the issue of a total
of 4,166,667 new Ordinary Shares to existing retail shareholders in
the United Kingdom.
The Fundraise, which is conditional
on Admission, raises gross proceeds of, in aggregate, £406,417, via
the issue of 63,569,573 Placing Shares pursuant to the Placing
and 4,166,667 WRAP Retail Offer Shares pursuant to the WRAP
Retail Offer.
Use
of Proceeds
In order to further develop its
business and accelerate growth, the Company targeted a raise of
£406,417 with the intention of using the net proceeds of the
fundraise towards activities including:
·
Recruitment of a Head of Mathematical Modelling
Service Line to accelerate conversion of the pipeline and drive
operational excellence.
·
Further investment in Business Development and
Marketing to build and strengthen the pipeline, expand into new
therapeutic areas, develop its data science offering and launch its
biostatistics offering.
·
Build a biostatistics capability, including team
expansion, development of processes, acquisition of necessary tools
and exploration of strategic options.
·
Implementation of the personalised dosing tool on
the DoseMeRx Platform, enabling it to be available to clinicians
across the US and deliver on a study in partnership with DoseMeRx
to further develop the tools G-CSF functionality.
Admission and Total Voting Rights
Applications have been made for the
Placing Shares and the WRAP Retail Offer Shares to be admitted to
trading on AIM, which is expected to take effect and dealings to
commence at 8:00 a.m. on or around 9 July 2024 ("Admission").
Following Admission, the Company
will have 203,208,718 Ordinary Shares in issue. Since the Company
currently holds no shares in treasury, the total number of voting
rights in the Company will be 203,208,718.These figure may be used
by shareholders of the Company as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
For
further information, please contact:
Physiomics plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James
Bellman
+44 (0)20 7409 3494
Winterflood Retail Access Platform
Joe Winkley & Sophia
Bechev
+44 (0)20 8100 0000
Further information on the Company
can be found on its website at www.physiomics.co.uk.
The Company's LEI is
213800A71DSZ6ABMTQ91.